Showing posts tagged with "small-molecules-and-synthetic-therapeutics"
Disulfide rich peptides are unique in both their incredibly high cysteine content, but also in the stability imbued by the multiple disulfide bonds. These peptides, stable under extreme conditions tha...
As peptide therapeutics continue to gain interest from the medical community and pharmaceutical companies, concerns regarding the cost of manufacturing also grow. Cost includes the expense of reagents...
I’ve recently worked with several peptide groups that are trying out flash purification with their peptides for the first time. And it never fails, every single interaction includes the question “what...
Big pharmaceutical companies have begun to refocus their efforts towards peptide discovery projects with the hopes of identifying the next big peptide drug. There are often hundreds to thousands of pe...
Covalent stapling strategies that stabilize a particular secondary structure have garnered much attention as interest in peptide therapeutics continues to grow. One such strategy - using olefin-bearin...
In a previous post, I evaluated how flow rate can impact my purification efficiency using flash chromatography. I noticed though, that my peptide eluted significantly later with high mobile phase flow...
Red Glead Discovery (RGD) is a pre-clinical drug discovery CRO offering a broad range of services to Life Science clients. With a focus on small molecules and peptides, their drug discovery platform r...
Every now and then I work with new groups as they embark on a journey incorporating peptides and peptide synthesis into their research. More often than not, no one in the group has experience with pep...
Side reactions. Words that cause a little shiver to run down every peptide chemists’ spine.
Aspartimide rearrangements are a particularly nasty side reaction that can occur during fmoc-based solid phase peptide synthesis. Not only is this a mass-neutral side reaction, chromatographically res...